Latest Commercialisation News

Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.

Prairie Lithium restructures its board to sharpen focus on commercial lithium production, with Paul Lloyd stepping up as Executive Chairman to lead corporate strategy and financing.

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.

GCM Corporation has inked a binding 24-month joint development agreement with Shenzhen Wanwei Heat Conduction Technology (ALVC) to co-develop a hybrid thermal management product combining vapour chamber and VHD heat sink technologies.

Ore Resources has accelerated its lithium exploration and development at Coolgardie with diamond and RC drilling programs, alongside advancing economic studies and permitting efforts.

Galilee Energy has raised the drilling derrick at its Zydeco-1 well in Louisiana, marking the last major pre-spud milestone. Drilling is set for early July 2026, aiming at a substantial Gulf Coast gas-condensate resource with rapid commercialisation potential.

Macarthur Minerals narrowed its loss to $1.82 million for FY26, bolstered by a major new investor and joint venture at its Lake Giles iron ore project in Western Australia.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

HITIQ Limited has secured $1.4 million through a private placement of 200 million shares at 0.7 cents each, accompanied by options exercisable until 2029. The capital will bolster its balance sheet and back expansion and commercialisation efforts.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.